Anti-angiogenic targets in the treatment of advanced renal cell carcinoma

Current Cancer Drug Targets

Volumn 8, Issue 8, 2008, Pages 676-682

  Heng, Daniel Y C ^a   Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Platelet derived growth factor; Renal cell carcinoma; Sorafenib; Sunitinib; Vascular endothelial growth factor

Indexed keywords

AG 028262; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CEDIRANIB; CP 673451; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 4; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANGIOGENESIS; BLEEDING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TARGETING; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; MUCOSA INFLAMMATION; PROTEINURIA; RASH; REVIEW; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; VON HIPPEL LINDAU DISEASE; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; LIGANDS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU DISEASE;

EID: 57449083438     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908786733450     Document Type: Review

References (33)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57, 43-66.
2. McDermott, D. F.; Regan, M. M.; Clark, J. I.; Flaherty, L. E.; Weiss, G. R.; Logan, T. F.; Kirkwood, J. M.; Gordon, M. S.; Sosman, J. A.; Ernstoff, M. S.; Tretter C. P.; Urba, W. J.; Smith, J. W.; Margolin, K. A.; Mier, J. W.; Gollob, J. A.; Dutcher, J. P.; Atkins, M. B. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2005, 23, 133-141.
3. Yang, J. C.; Sherry, R. M.; Steinberg, S. M.; Topalian, S. L.; Schwartzentruber, D. J.; Hwu, P.; Seipp, C. A.; Rogers-Freezer, L.; Morton, K. E.; White, D. E.; Liewehr, D. J.; Merino, M. J.; Rosenberg, S. A. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 2003, 21, 3127-3132.
4. Negrier, S.; Escudier, B.; Lasset, C.; Douillard, J. Y.; Savary, J.; Chevreau, C.; Ravaud, A.; Mercatello, A.; Peny, J.; Mousseau, M.; Philip, T.; Tursz, T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. groupe francais d'immunotherapie. N. Engl. J. Med. 1998, 338, 1272-1278.
5. Coppin, C.; Porzsolt, F.; Awa, A.; Kumpf, J.; Coldman, A.; Wilt, T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 2005, (1):CD001425.
6. Cohen, H. T.; McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 2005, 353, 2477-2490.
7. Rini, B. I.; Small, E. J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 2005, 23, 1028-1043.
8. Banks, R. E.; Tirukonda, P.; Taylor, C.; Hornigold, N.; Astuti, D.; Cohen, D.; Maher, E. R.; Stanley, A. J.; Harnden, P.; Joyce, A.; Knowles, M.; Selby, P. J. Genetic and epigenetic analysis of von hippel-lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res. 2006, 66, 2000-2011.
9. Gnarra, J. R.; Tory, K.; Weng, Y.; Schmidt, L.; Wei, M. H.; Li, H.; Latif, F.; Chen, F.; Duh, F. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 1994, 7, 85-90.
10. Shuin, T.; Kondo, K.; Torigoe, S.; Kishida, T.; Kubota, Y.; Hosaka, M.; Nagashima, Y.; Kitamura, H.; Latif, F.; Zbar, B. Frequent somatic mutations and loss of heterozygosity of the von hippel-lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 1994, 54, 2852-2855.
11. Kondo, K.; Yao, M.; Yoshida, M.; Kishida, T.; Shuin, T.; Miura, T.; Moriyama, M.; Kobayashi, K.; Sakai, N.; Kaneko, S.; Kawakami, S.; Baba, M.; Nakaigawa, N.; Nagashima, Y.; Nakatani, Y.; Hosaka, M. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002, 34, 58-68.
12. Brauch, H.; Weirich, G.; Brieger, J.; Glavac, D.; Rodl, H.; Eichinger, M.; Feurer, M.; Weidt, E.; Puranakanitstha, C.; Neuhaus, C.; Pomer, S.; Brenner, W.; Schirmacher, P.; Storkel, S.; Rotter, M.; Masera, A.; Gugeler, N.; Decker, H. J. VHL alterations in human clear cell renal cell carcinoma: Association with advanced tumor stage and a novel hot spot mutation. Cancer Res. 2000, 60, 1942-1948.
13. Kenck, C.; Wilhelm, M.; Bugert, P.; Staehler, G.; Kovacs, G. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J. Pathol. 1996, 179, 157-161.
14. Clifford, S. C.; Prowse, A. H.; Affara, N. A.; Buys, C. H.; Maher, E. R. Inactivation of the von hippel-lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL-independent pathway in clear cell renal umourigenesis. Genes Chromosomes Cancer 1998, 22, 200-209.
15. Foster, K.; Prowse, A.; van den Berg, A.; Fleming, S.; Hulsbeek, M. M.; Crossey, P. A.; Richards, F. M.; Cairns, P.; Affara, N. A.; Ferguson-Smith, M. A. Somatic mutations of the von hippel-lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 1994, 3, 2169-2173.
16. Folkman, J. Angiogenesis: An organizing principle for drug discovery? Nat. Rev. Drug Discov. 2007, 6, 273-286.
17. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3, 401-410.
18. Jacobsen, J.; Rasmuson, T.; Grankvist, K.; Ljungberg, B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. 2000, 163, 343-347.
19. Presta, L. G.; Chen, H.; O'Connor, S. J.; Chisholm, V.; Meng, Y. G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57, 4593-4599.
20. Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; Gorbunova, V.; Bay, J. O.; Bodrogi, I.; Jagiello-Gruszfeld, A.; Moore, N.; AVOREN Trial Investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007, 370, 2103-2111.
21. Christensen, J. G. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann. Oncol. 2007, 18(Suppl. 10), x3-10.
22. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbutherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9, 327-337.
23. Motzer, R. J.; Rini, B. I.; Bukowski, R. M.; Curti, B. D.; George, D. J.; Hudes, G. R.; Redman, B. G.; Margolin, K. A.; Merchan, J. R.; Wilding, G.; Ginsberg, M. S.; Bacik, J.; Kim, S. T.; Baum, C. M.; Michaelson, M. D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295, 2516-2524.
24. Motzer, R. J.; Michaelson, M. D.; Redman, B. G.; Hudes, G. R.; Wilding, G.; Figlin, R. A.; Ginsberg, M. S.; Kim, S. T.; Baum, C. M.; DePrimo, S. E.; Li, J. Z.; Bello, C. L.; Theuer, C. P.; George, D. J.; Rini, B. I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24, 16-24.
25. Motzer, R. J.; Hutson, T. E.; Tomczak, P.; Michaelson, M. D.; Bukowski, R. M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S. T.; Chen, I.; Bycott, P. W.; Baum, C. M.; Figlin, R. A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 115-124.
26. Motzer, R. J.; Bacik, J.; Murphy, B. A.; Russo, P.; Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002, 20, 289-296.
27. Ahmad, T.; Eisen, T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin. Cancer Res. 2004, 10, 6388S-6392S.
28. Escudier, B.; Eisen, T.; Stadler, W. M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A. A.; Rolland, F.; Demkow, T.; Hutson, T. E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R. M.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 125-134.
29. Rixe, O.; Bukowski, R. M.; Michaelson, M. D.; Wilding, G.; Bolte, O.; Motzer, R. J.; Bycott, P.; Liau, K. F.; Freddo, J.; Trask, P. C.; Kim, S.; Rini, B. I. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 2007, 8, 975-984.
30. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wold, I. G.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R. J. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 2271-2281.
31. Heng, D. Y.; Bukowski, R. M. Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma. Oncol. Rev. 2007, 1, 170-176.
32. Choueiri, T. K.; Plantade, A.; Elson, P.; Negrier, S.; Ravaud, A.; Oudard, S.; Zhou, M.; Rini, B. I.; Bukowski, R. M.; Escudier, B. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 2008, 26(1), 127-131.
33. Bukowski, R. M.; Kabbinavar, F. F.; Figlin, R. A.; Flaherty, K.; Srinivas, S.; Vaishampayan, U.; Drabkin, H. A.; Dutcher, J.; Ryba, S.; Xia, Q.; Scappaticci, F. A.; McDermott, D. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 2007, 25, 4536-4541.